DaVita (NYSE:DVA) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

DaVita (NYSE:DVA) posted its earnings results on Monday. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16, FiscalAI reports. The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.24 earnings per share. DaVita updated its FY 2026 guidance to 13.600-15.00 EPS.

Here are the key takeaways from DaVita’s conference call:

• IKC reached profitability in 2025 — DaVita reported its first profitable full year for Integrated Kidney Care, citing better patient outcomes (e.g., higher permanent vascular access rates, fewer infections) and expects an incremental $20 million of IKC operating income in 2026.
• 2026 guidance is constructive: adjusted operating income of $2.085B–$2.235B (midpoint ~3.2% growth), adjusted EPS guidance of $13.60–$15.00 (company cites ~33% growth at midpoint), and free cash flow of $1.0B–$1.25B.
• Near-term headwinds include elevated mortality pressuring treatment growth (U.S. treatments down ~1.1% for 2025), higher patient care costs per treatment (+5.9% YoY), and an estimated ~$40M 2026 RPT hit from the expiration of enhanced premium tax credits.
• Revenue per treatment accelerated in Q4 (≈+$12 sequential and full-year RPT ≈$410, +4.7%), driven by resolution of aged receivables, rate increases, slightly better private-pay mix and seasonal vaccine impacts; 2026 RPT is forecast at ~1%–2% growth with some timing quirks (Q1 seasonality/headwinds).
• Capital allocation remains shareholder-friendly: nearly 13M shares repurchased (~$1.8B) in 2025, leverage at a mid-target 3.26x, and a roughly $200M minority investment in Elara Caring to expand home-based ESKD services (expected to close mid-year and to contribute to other income).

DaVita Stock Performance

NYSE:DVA opened at $111.21 on Tuesday. The stock has a market capitalization of $7.85 billion, a PE ratio of 11.45, a P/E/G ratio of 0.67 and a beta of 0.99. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $178.47. The company has a fifty day moving average of $113.42 and a two-hundred day moving average of $124.86.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 EPS beat — DaVita reported $3.40 EPS, above Zacks’ $3.24 estimate and ahead of other consensus figures, signaling better-than-expected profitability for the quarter. DaVita HealthCare (DVA) Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Revenue beat and growth — Total Q4 revenue was $3.62B (≈+9.9% YoY), above analyst estimates, supporting the top‑line beat and suggesting steady demand for dialysis services. DaVita Inc. 4th Quarter 2025 Results
• Positive Sentiment: Raised FY‑2026 guidance — Management set EPS guidance of $13.60–$15.00 for FY‑2026, above the consensus (~$12.80), a key driver of the post‑earnings rally. Reuters notes the company forecast profit above estimates on steady dialysis demand. DaVita forecasts 2026 profit above estimates
• Neutral Sentiment: Mixed operating metrics — Detailed filings show revenue and operating profit improved materially (gross profit +13%, operating profit +~37%), but net income and cash balances were down YoY and liabilities increased — a mixed signal for longer‑term cash generation. DaVita Inc. (DVA) Releases Q4 2025 Earnings
• Negative Sentiment: Institutional selling and analyst caution — Recent filings show significant position reductions by large holders (e.g., Berkshire Hathaway trimmed exposure in prior quarters) and at least one underperform rating remains, which could cap upside if selling continues. DaVita Inc. (DVA) Releases Q4 2025 Earnings (institutional moves & targets)

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of DVA. CIBC Private Wealth Group LLC boosted its holdings in DaVita by 19.7% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,628 shares of the company’s stock worth $349,000 after buying an additional 432 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of DaVita in the third quarter worth approximately $683,000. Danske Bank A S purchased a new stake in shares of DaVita during the third quarter worth approximately $2,852,000. Advisory Services Network LLC acquired a new position in DaVita in the 3rd quarter valued at $115,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in DaVita during the 3rd quarter worth $203,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the topic of a number of recent research reports. UBS Group restated a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Truist Financial lowered their price objective on DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research report on Monday, January 5th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Zacks Research upgraded shares of DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.